Tuberculosis Diagnostics Test Market Size & Share 2026-2035

Tuberculosis Diagnostics Test Market Size

The tuberculosis diagnostics test market was valued at USD 2.57 billion in 2025, is projected to reach USD 2.71 billion in 2026, and is expected to expand at a 5.4% CAGR (2026–2035) to reach USD 4.35 billion by 2035.

The market includes molecular, immunological, laboratory, radiographic, serological, and emerging diagnostic products used to detect active tuberculosis, identify latent tuberculosis infection, characterize drug resistance, and support treatment monitoring.

Demand is shifting from low-sensitivity frontline methods toward faster, more actionable diagnostic pathways. National TB programs are prioritizing molecular confirmation and drug-resistance detection, while high-income health systems are sustaining immunological test consumption through latent-infection screening in occupational health, migration health, and specialty-care pathways. This produces two distinct commercial demand pools: decentralized public-health testing in high-burden settings and recurring laboratory-based screening in lower-incidence markets.

Tuberculosis Diagnostics Test Market Trends, Growth Drivers & GMI Forecast Outlook

The market outlook reflects a tension between clinically urgent demand for faster tuberculosis detection and the financial, operational, and regulatory constraints that determine whether advanced tests reach frontline settings. Molecular testing, reflex drug-susceptibility workflows, and latent-infection screening are broadening the revenue base, but realization remains uneven across procurement environments.

Key Drivers

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

Drug-resistant disease changes the economic value of a positive diagnostic result because it creates an immediate need for further characterization, rather than a single confirmatory test. WHO reported 400,000 MDR/RR-TB cases in 2023, reinforcing the importance of molecular workflows that can identify resistance early enough to influence treatment selection. ^{[3]World Health Organization. "1.3 Drug-Resistant TB - Global Tuberculosis Report 2024." who.int} This favors platforms that can connect initial detection to reflex testing without introducing specimen-transfer delays or fragmented laboratory accountability.

A separate growth channel is emerging through latent tuberculosis infection screening. Interferon-gamma release assays are increasingly embedded in protocols for healthcare workers, migrants, and patients being evaluated for immunosuppressive therapies. Unlike active-disease diagnostics, this demand is shaped less by local transmission intensity than by reimbursement structures, clinical guidelines, and the continuity of institutional screening programs.

Key Restraints

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

Infrastructure limitations are not confined to instrument acquisition. Reliable electricity, temperature control, trained operators, service contracts, reagent logistics, and replacement capacity all influence whether a molecular platform can sustain routine use after installation. These constraints make procurement success dependent on the operating model around the test, particularly in decentralized care networks.

The installed molecular base is substantial, but its distribution remains concentrated. Approximately 20 million Xpert cartridges were procured globally in 2022, demonstrating the scale of existing rapid-testing infrastructure while also highlighting the commercial importance of recurring consumables and dependable field support. ^{[4]The Global Fund to Fight AIDS, Tuberculosis and Malaria. "Global Fund, Stop TB Partnership and USAID Announce New Collaboration with Danaher to Reduce Price and Increase Access to Cepheid's TB Test." theglobalfund.org} Manufacturers that can combine low-complexity workflows with serviceable logistics are better positioned where public programs seek broader access without proportionate increases in laboratory complexity.

Tuberculosis Diagnostics Test Market Segment Analysis

By Test Type

The tuberculosis diagnostics test market's molecular diagnostics segment generated USD 821 million in 2025 and is expected to reach USD 1.65 billion by 2035. Molecular demand is being sustained by the replacement of smear-led diagnostic algorithms with rapid nucleic-acid testing, particularly where national programs need quicker confirmation and earlier identification of rifampicin resistance. Cartridge-based systems remain central to decentralized deployment, while sequencing and advanced resistance panels create a higher-complexity growth path for referral laboratories.

Immunological tests accounted for 36.0% of market revenue in 2025 and are projected to reach USD 1.57 billion by 2035. The category is increasingly shaped by IGRA adoption in latent-infection pathways, where a blood-based test can fit occupational health, migration screening, and pre-biologic treatment workflows more readily than a multi-visit skin-test protocol. TST products remain important where laboratory infrastructure is limited, but the revenue mix continues to favor automated and higher-value immunological testing formats.

Laboratory methods generated USD 410 million in 2025 and are projected to grow at a 2.4% CAGR (2026–2035). Culture and smear-based methods retain a necessary reference role in viable-organism recovery and phenotypic drug-susceptibility assessment, even as their frontline use is displaced by rapid molecular testing. Their commercial durability therefore rests on complex-case management and reference-laboratory work rather than broad screening expansion.

Radiographic diagnostics are projected to reach USD 392 million by 2035 and expand at a 6.7% CAGR (2026–2035). Digital chest X-ray and AI-enabled computer-aided detection are becoming more useful as screening-enablement tools where sputum collection, sample transport, or laboratory access creates bottlenecks. Their value proposition is strongest when imaging is integrated with confirmatory molecular testing rather than positioned as a standalone diagnostic substitute.

Serological tests represented 3.0% of market revenue in 2025 and are expected to account for 1.0% by 2035. Regulatory and clinical disfavor toward antibody-based active-TB testing is narrowing the segment's long-term role, even where private-sector availability persists. The outlook is defined by declining clinical acceptance rather than technology-led expansion.

Others, including lipoarabinomannan assays and biosensor platforms, generated USD 129 million in 2025 and are expected to reach USD 174 million by 2035. LF-LAM testing has particular relevance in HIV-associated tuberculosis pathways, where rapid testing can address urgent diagnostic needs among severely immunocompromised patients. Biosensor platforms remain earlier-stage, but their potential value lies in bringing connected, near-patient diagnostics closer to community care settings.

By Modality

Point-of-care testing generated USD 462 million in 2025 and is anticipated to grow at an 8.5% CAGR (2026–2035). Growth reflects the movement of diagnostic capacity toward primary health centers, community clinics, and mobile services that need closed, low-complexity workflows. The commercial opportunity depends on whether deployment programs align instrument installation, training, maintenance, connectivity, and consumable supply within the same implementation cycle.

Laboratory-based testing represented 82.0% of market revenue in 2025 and is projected to reach USD 3.31 billion by 2035. Reference laboratories remain indispensable for culture, high-throughput IGRA processing, complex molecular testing, and advanced drug-resistance characterization. Although decentralized testing is expanding, laboratory networks retain the breadth of capability required for confirmation, surveillance, and difficult clinical cases.

By End Use

Pathological laboratories generated USD 975 million in 2025 and are forecast to grow at a 4.2% CAGR (2026–2035). Their role remains anchored in culture, high-complexity molecular assays, sequencing, and immunological test processing. The segment is not being displaced so much as repositioned: frontline testing is moving outward, while laboratories concentrate increasingly on confirmatory and technically demanding workflows.

Hospitals & clinics accounted for 35.0% of market revenue in 2025 and are expected to reach USD 1.48 billion by 2035. These settings concentrate drug-resistant TB workups, pediatric and extrapulmonary disease evaluation, and testing for medically complex patients. Hospital demand is also reinforced by specialty-care protocols that require latent-infection assessment before biologic therapy or other immunosuppressive treatment.

Point-of-care & primary healthcare centers generated USD 359 million in 2025 and are projected to grow at a 9.8% CAGR (2026–2035). This is the clearest commercial expression of diagnostic decentralization, with public-health programs extending automated molecular systems, portable imaging, and low-complexity assays beyond the hospital tier. The segment's potential is substantial, but its growth remains dependent on durable local operating capacity rather than technology availability alone.

Other end users, including research institutes, NGOs, and specialized public-health laboratories, accounted for 13.0% of market revenue in 2025 and are expected to reach USD 479 million by 2035. Demand in this group is shaped by elimination initiatives, outbreak-response programs, research activity, and donor-supported procurement. As a result, purchasing patterns can be episodic and closely linked to program milestones and funding cycles.

Tuberculosis Diagnostics Test Market Regional Analysis

North America Tuberculosis Diagnostics Test Market Analysis

The tuberculosis diagnostics test market in North America generated USD 692 million in 2025 and is projected to grow at a 4.2% CAGR (2026–2035). Regional demand is driven primarily by latent-infection screening, occupational health protocols, and specialty-care testing rather than broad active-disease volume. Mature laboratory networks support recurring IGRA utilization and targeted molecular testing through public-health and clinical referral channels.

United States

The United States generated USD 657 million in 2025 and is expected to reach USD 991 million by 2035. The market is anchored by IGRA-based latent-infection screening across reference laboratories, hospital systems, occupational health providers, and immigration-related services. Molecular testing and targeted imaging remain important in public-health programs serving higher-risk populations, but recurring immunological screening provides the most stable commercial base.

Canada

Canada's demand is oriented toward latent-infection screening for immigration, occupational health, and contact investigation programs, supported by provincial public-health procurement. The market remains smaller than the United States, but its testing mix similarly favors IGRA use and centralized molecular confirmation within structured healthcare pathways.

Europe Tuberculosis Diagnostics Test Market Analysis

Europe represented 22.0% of market revenue in 2025 and is expected to reach USD 914 million by 2035. The regional market is supported by established IGRA adoption, migrant-health screening, and well-developed referral laboratory infrastructure for culture and drug-susceptibility testing. Growth is steady rather than explosive because diagnostic coverage is already comparatively mature across major Western European systems.

Germany

Germany generated USD 124 million in 2025 and is projected to reach USD 201 million by 2035. Broad reimbursement support for IGRA testing and a strong laboratory network underpin demand, while molecular and sequencing capability supports resistance surveillance and referral testing. Germany's position as a clinical and laboratory hub strengthens its role in higher-complexity diagnostic workflows.

United Kingdom

The United Kingdom accounted for 4.4% of market revenue in 2025 and is expected to reach USD 183 million by 2035. Demand is shaped by latent-infection screening in new-entrant health assessments and contact investigations, alongside centralized molecular, culture, and drug-susceptibility services. Urban concentration of active cases supports continued need for coordinated public-health laboratory capacity.

France

France generated USD 79 million in 2025 and is expected to expand at a 4.9% CAGR (2026–2035). Screening among high-risk communities, immigrant health programs, and public-hospital molecular capacity support the market. The country's outlook depends on maintaining integrated links between targeted screening and rapid referral for confirmatory testing.

Italy

Italy is expected to reach USD 110 million by 2035 and represented 2.7% of market revenue in 2025. Demand is concentrated in urban and northern regional health systems where active-disease confirmation and latent-infection management serve diverse foreign-born and higher-risk populations. Investment in NAAT capacity is strengthening time-to-diagnosis in these settings.

Spain

Spain accounted for 2.2% of market revenue in 2025 and is projected to reach USD 91 million by 2035. Its demand profile combines NAAT-based active-disease testing with occupational and public-health screening. Metropolitan care networks and migrant-health services remain important channels for sustaining utilization.

Netherlands

The Netherlands generated USD 45 million in 2025 and is expected to reach USD 73 million by 2035. Structured new-entrant screening and established IGRA infrastructure support a relatively resilient latent-infection testing base. Reference-laboratory capability further reinforces the market's emphasis on quality-assured diagnostic pathways.

Rest of Europe

Rest of Europe generated USD 79 million in 2025 and is expected to reach USD 128 million by 2035. Central and Eastern European markets present a different demand mix from Western Europe, with drug-resistant disease and the need for molecular drug-susceptibility testing carrying greater commercial weight. Investment in reflex testing and surveillance infrastructure is central to the regional opportunity.

Asia Pacific Tuberculosis Diagnostics Test Market Analysis

The tuberculosis diagnostics test market in Asia Pacific generated USD 949 million in 2025 and is expected to account for 40.0% of market revenue by 2035. The region combines the largest disease burden with widening government investment in molecular capacity, decentralized testing, and domestic manufacturing. Its outlook is determined by how quickly national programs can replace smear-led pathways with scalable NAAT-first algorithms.

China

China generated USD 332 million in 2025 and is expected to account for 14.0% of market revenue by 2035. National program investment, county-level diagnostic deployment, and domestic instrument manufacturing are reshaping the competitive environment. Local supply can accelerate volume adoption, but it also intensifies pricing pressure on imported platforms in public procurement.

India

India is expected to reach USD 522 million by 2035 and expand at a 6.2% CAGR (2026–2035). The country's market is supported by large-scale molecular testing deployment through the national TB program, including near-patient infrastructure designed to reach lower-level facilities. Sustained growth will depend on instrument uptime, consumable availability, workforce readiness, and the consistency of public funding.

Japan

Japan generated USD 171 million in 2025 and is expected to reach USD 313 million by 2035. The market is characterized by high vigilance, broad access to immunological testing, and strong laboratory capability for active-disease confirmation. In a lower-incidence environment, diagnostic value is concentrated in surveillance, clinical certainty, and targeted screening.

South Korea

South Korea represented 3.0% of market revenue in 2025 and is expected to reach USD 139 million by 2035. High adoption of IGRA testing in healthcare, contact investigation, and immigration-related settings supports a valuable screening market. Its infrastructure quality also favors advanced laboratory workflows for confirmation and follow-up.

Australia

Australia generated USD 38 million in 2025 and is expected to reach USD 70 million by 2035. The market is small but technically mature, with established IGRA use and reference-laboratory capability. Immigration health processing and regional referral activity provide stable demand despite relatively limited domestic active-disease volume.

Rest of Asia Pacific

Rest of Asia Pacific represented 1.8% of market revenue in 2025 and is expected to reach USD 87 million by 2035. The grouping includes high-burden countries where donor-supported deployment of GeneXpert, Truenat, and related technologies is expanding diagnostic access. Revenue realization remains sensitive to tender structures and the sustainability of external financing.

Latin America Tuberculosis Diagnostics Test Market Analysis

Latin America generated USD 154 million in 2025 and is projected to grow at a 7.1% CAGR (2026–2035). The region's growth reflects underpenetrated molecular testing, recovery of TB-program investment, and a healthcare financing profile that can support broader NAAT adoption. Fragmented purchasing structures remain a constraint, but they also create opportunities for suppliers that can support local implementation and service needs.

Brazil

Brazil generated USD 69 million in 2025 and is projected to grow at a 7.1% CAGR (2026–2035). The country benefits from structured public-health capacity and a national diagnostic pathway that incorporates molecular testing. Its ability to scale community-level testing is stronger than many regional peers because laboratory networks and public procurement mechanisms are comparatively established.

Mexico

Mexico represented 1.3% of market revenue in 2025 and is expected to reach USD 67 million by 2035. Molecular diagnostic uptake is being supported by public health-system procurement and gradual improvements in laboratory infrastructure. Border-region demand and migrant-health needs add a targeted use case for faster confirmation pathways.

Argentina

Argentina generated USD 18 million in 2025 and is projected to grow at a 7.5% CAGR (2026–2035). Recovery in program activity and a relatively developed laboratory base create room for higher-complexity testing adoption. The country's growth potential depends on the resilience of diagnostic budgets and procurement continuity.

Rest of Latin America

Rest of Latin America is expected to reach USD 64 million by 2035 and expand at a 6.8% CAGR (2026–2035). Diverse disease burdens and purchasing capacities make the region fragmented, but molecular testing needs are rising across countries with persistent transmission and expanding program support. Commercial success will require country-specific channels rather than a uniform regional model.

Middle East & Africa Tuberculosis Diagnostics Test Market Analysis

Middle East & Africa represented 8.0% of market revenue in 2025 and is expected to reach USD 348 million by 2035. The region spans advanced Gulf healthcare systems and severely resource-constrained African TB programs, producing uneven demand for molecular, immunological, and decentralized diagnostics. Financing structures, donor transitions, and local service capacity will determine how much need converts into manufacturer revenue.

Saudi Arabia

Saudi Arabia is projected to reach USD 63 million by 2035 and grow at a 5.5% CAGR (2026–2035). Demand is supported by expatriate health screening, pilgrim-health protocols, and hospital-based active-disease confirmation. The market favors accredited molecular and immunological platforms that can meet both public and private healthcare requirements.

UAE

The UAE represented 1.0% of market revenue in 2025 and is expected to reach USD 42 million by 2035. Private-sector diagnostic spending, workforce health programs, and expatriate healthcare services support a growing role for IGRA testing. The market's commercial profile is more value-oriented than volume-oriented.

South Africa

South Africa generated USD 52 million in 2025 and is expected to account for 2.0% of market revenue by 2035. Its dense molecular testing footprint and high HIV-TB co-infection burden support demand across NAAT, LF-LAM, culture, and imaging pathways. Continued funding and operational support for testing infrastructure remain critical to maintaining utilization.

Rest of MEA

Rest of MEA represented 3.6% of market revenue in 2025 and is expected to reach USD 155 million by 2035. High burden does not automatically translate into high revenue because procurement is often donor-priced and infrastructure constrained. Rising national co-financing requirements could broaden domestic purchasing over time, but affordability and field-service capacity will remain decisive.

Tuberculosis Diagnostics Test Market Share & Competitive Landscape

The tuberculosis diagnostics test market share landscape is moderately concentrated, with leading participants differentiated by installed base, assay menus, laboratory relationships, public-health procurement access, and their ability to serve both latent-infection and active-disease pathways. Competitive intensity is increasing as established molecular and culture franchises face pressure from portable NAAT systems, automated IGRA processing, AI-supported imaging, and sequencing-based resistance testing.

Qiagen held a 14.8% market share in 2025. Its position is closely tied to the QuantiFERON-TB Gold Plus franchise and the durability of IGRA demand in higher-income latent-infection screening programs. The company's strategic strength lies in recurring consumption through established clinical and laboratory workflows, where reimbursement relationships and standardized screening protocols create meaningful qualification barriers.

bioMerieux accounted for a 9.7% market share in 2025. Its culture and drug-susceptibility testing franchise provides recurring demand from reference laboratories that require validated workflows for complex TB cases. The company is also extending its relevance in molecular and sequencing-enabled resistance characterization, positioning it to participate in the shift from single-result diagnostics toward more information-rich testing pathways.

Cepheid, part of Danaher, held a 7.5% market share in 2025. The GeneXpert ecosystem gives the company a major installed-base advantage in rapid molecular testing, particularly in public-sector and high-burden settings. However, its leadership is exposed to procurement-driven pricing pressure and expanding competition from lower-complexity alternatives designed for decentralized molecular testing.

BD and bioMerieux remain influential in laboratory methods through culture systems and consumables, where technical validation, reference-laboratory relationships, and clinical confidence create durable barriers to substitution. Revvity, through Oxford Immunotec, remains a central competitor in IGRA testing, while Roche, Abbott, Thermo Fisher Scientific, Siemens Healthineers, and DiaSorin participate through broader molecular, immunodiagnostic, and automated laboratory platforms.

Hain Lifescience, a Bruker company, retains a specialized role in line probe assays for drug-resistance detection. Molbio Diagnostics is building relevance in decentralized molecular testing through the Truenat platform, particularly where procurement agencies seek alternatives to established cartridge systems. SD Biosensor, Anhui Zhifei Longcom, Trivitron Healthcare, and LumiraDx are active in adjacent rapid-testing, domestic-platform, and near-patient opportunities, although sustained commercial scale will depend on clinical validation, procurement qualification, and service execution.

Recent Industry Developments

Cepheid Xpert MTB/XDR receives WHO prequalification. In October 2025, WHO prequalified Cepheid's Xpert MTB/XDR test, expanding the company's potential access to international public-health procurement channels for drug-resistant tuberculosis diagnostics. The test is designed to identify resistance markers directly from sputum specimens on the GeneXpert system, reinforcing Cepheid's position in molecular drug-susceptibility testing. ^{[5]WHO Prequalification Programme. "WHO Has Listed an Additional TB Test - Xpert MTB/XDR." extranet.who.int}

bioMerieux and Oxford Nanopore launch AmPORE-TB for research use. In November 2025, bioMerieux and Oxford Nanopore launched AmPORE-TB, a research-use sequencing solution intended to characterize drug-resistance markers in Mycobacterium tuberculosis complex. The launch signals rising commercial interest in faster sequencing-enabled resistance characterization, though broader clinical adoption will depend on regulatory progression and laboratory implementation. ^{[6]bioMerieux. "Oxford Nanopore and bioMerieux Launch AmPORE-TB, a Research Use Only Sequencing-Based Solution to Rapidly Characterize Drug-Resistant Tuberculosis." biomerieux.com}